Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818779 · ClinicalTrials.gov registry record · Phase 4
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
A Phase 4 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT00818779 is a Phase 4 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 38 participants.
The verdict
NCT00818779, a Phase 4 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818779
The ClinicalTrials.gov registry entry for NCT00818779 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amlodipine is the first listed.
NCT00818779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00818779 about?
NCT00818779 is a clinical study titled "Direct Renin Inhibition Effects on Atherosclerotic Biomarkers". The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calc...
What is the current status of trial NCT00818779?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2008-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00818779?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00818779?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.